Summit, NJ, United States of America

Jeff Schkeryantz

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jeff Schkeryantz: Innovator in Sphingosine 1 Phosphate Receptor Modulation

Introduction

Jeff Schkeryantz is a notable inventor based in Summit, NJ (US). He has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate the sphingosine-1-phosphate receptor. With a total of 3 patents to his name, Schkeryantz's work has implications for various medical conditions.

Latest Patents

Among his latest patents, Schkeryantz has developed compounds characterized by the structure of Formula (I), which can include pharmaceutically acceptable salts, homologs, hydrates, or solvates. These compounds serve as modulators of the sphingosine-1-phosphate receptor, which is crucial for treating conditions where receptor activation is medically indicated. His innovative approach in this area has the potential to lead to new therapeutic options.

Career Highlights

Jeff Schkeryantz is currently associated with Receptos, Inc., where he continues to advance his research and development efforts. His work at Receptos has positioned him as a key player in the pharmaceutical industry, focusing on innovative solutions for complex health issues.

Collaborations

Throughout his career, Schkeryantz has collaborated with notable colleagues, including Roger Bakale and Maurice Marsini. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

In summary, Jeff Schkeryantz is a distinguished inventor whose work in sphingosine-1-phosphate receptor modulation is paving the way for new medical treatments. His contributions to the field are invaluable and continue to impact the pharmaceutical landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…